|
1
|
National Cancer Institute: Surveillance,
Epidemiology, and End Results Program. SEER Stat Fact Sheets:
Pancreas Cancer. http://seer.cancer.gov/statfacts/html/pancreas.htmlAccessed.
April 08–2015
|
|
2
|
Han H and Von Hoff DD: SnapShot:
Pancreatic cancer. Cancer Cell. 23:424. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Winter JM, Yeo CJ and Brody JR:
Diagnostic, prognostic, and predictive biomarkers in pancreatic
cancer. J Surg Oncol. 107:15–22. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hammond E, Khurana A, Shridhar V and
Dredge K: The Role of Heparanase and Sulfatases in the Modification
of Heparan Sulfate Proteoglycans within the Tumor Microenvironment
and Opportunities for Novel Cancer Therapeutics. Front Oncol.
4:1952014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takahashi H and Shibuya M: The vascular
endothelial growth factor (VEGF)/VEGF receptor system and its role
under physiological and pathological conditions. Clin Sci (Lond).
109:227–241. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hosoki T: Dynamic CT of pancreatic tumors.
AJR Am J Roentgenol. 140:959–965. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matsubara H, Itoh A, Kawashima H, Kasugai
T, Ohno E, et al: Dynamic quantitative evaluation of
contrast-enhanced endoscopic ultrasonography in the diagnosis of
pancreatic diseases. Pancreas. 40:1073–1079. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Omoto I, Matsumoto M, Okumura H, Uchikado
Y, Setoyama T, Kita Y, Owaki T, Kijima Y, Shinchi H, Ishigami S, et
al: Expression of vascular endothelial growth factor-C and vascular
endothelial growth factor receptor-3 in esophageal squamous cell
carcinoma. Oncol Lett. 7:1027–1032. 2014.PubMed/NCBI
|
|
9
|
de Oliveira ATT, Reis RM, Afonso J,
Martinho O, Matos D, Carvalho AL, Vazquez VL, Silva TB,
Scapulatempo C, Saad SS, et al: Lymphangiogenic VEGF-C and VEGFR-3
expression in genetically characterised gastrointestinal stromal
tumours. Histol Histopathol. 26:1499–1507. 2011.PubMed/NCBI
|
|
10
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bustin SA, Benes V, Garson JA, Hellemans
J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL,
et al: The MIQE guidelines: Minimum information for publication of
quantitative real-time PCR experiments. Clin Chem. 55:611–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Neuzillet C, Sauvanet A and Hammel P:
Prognostic factors for resectable pancreatic adenocarcinoma. J Visc
Surg. 148:e232–e243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Argon A, Nart D, Oruc N, Coker A and
Ozutemiz O: The prognostic significance of clinicopathological
features and apoptosis inhibitor proteins in pancreas ductal
adenocarcinoma. Acta Gastroenterol Belg. 77:229–234.
2014.PubMed/NCBI
|
|
14
|
Jung KW, Kim MH, Lee TY, Kwon S, Oh HC,
Lee SS, Seo DW and Lee SK: Clinicopathological aspects of 542 cases
of pancreatic cancer: A special emphasis on small pancreatic
cancer. J Korean Med Sci. 22(Suppl): S79–S85. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gou HF, Chen XC, Zhu J, Jiang M, Yang Y,
Cao D and Hou M: Expressions of COX-2 and VEGF-C in gastric cancer:
Correlations with lymphangiogenesis and prognostic implications. J
Exp Clin Cancer Res. 30:142011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kozlowski M, Naumnik W, Niklinski J,
Milewski R, Dziegielewski P and Laudanski J: Vascular endothelial
growth factor C and D expression correlates with lymph node
metastasis and poor prognosis in patients with resected esophageal
cancer. Neoplasma. 58:311–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang KJ and Sui LH: The relevance and
role of vascular endothelial growth factor C, matrix
metalloproteinase-2 and E-cadherin in epithelial ovarian cancer.
Med Oncol. 29:318–323. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun GG, Wang YD, Cui DW, Cheng YJ and Hu
WN: EMP1 regulates caspase-9 and VEGFC expression and suppresses
prostate cancer cell proliferation and invasion. Tumour Biol.
35:3455–3462. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ciobanu M, Eremia IA, Crăiţoiu S,
Mărgăritescu CL, Stepan A, Pătraşcu V, Georgescu CC, Cernea D and
Dumitrescu D: Lymphatic microvessels density, VEGF-C, and VEGFR-3
expression in 25 cases of breast invasive lobular carcinoma. Rom J
Morphol Embryol. 54:925–934. 2013.PubMed/NCBI
|
|
20
|
Kurahara H, Takao S, Maemura K, Shinchi H,
Natsugoe S and Aikou T: Impact of vascular endothelial growth
factor-C and -D expression in human pancreatic cancer: Its
relationship to lymph node metastasis. Clin Cancer Res.
10:8413–8420. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Perrot-Applanat M and Di Benedetto M:
Autocrine functions of VEGF in breast tumor cells Adhesion,
survival, migration and invasion. Cell Adhes Migr. 6:547–553. 2012.
View Article : Google Scholar
|
|
22
|
Decio A, Taraboletti G, Patton V, Alzani
R, Perego P, Fruscio R, Jürgensmeier JM, Giavazzi R and Belotti D:
Vascular endothelial growth factor c promotes ovarian carcinoma
progression through paracrine and autocrine mechanisms. Am J
Pathol. 184:1050–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zetser A, Bashenko Y, Edovitsky E,
Levy-Adam F, Vlodavsky I and Ilan N: Heparanase induces vascular
endothelial growth factor expression: Correlation with p38
phosphorylation levels and Src activation. Cancer Res.
66:1455–1463. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zetser A, Levy-Adam F, Kaplan V,
Gingis-Velitski S, Bashenko Y, Schubert S, Flugelman MY, Vlodavsky
I and Ilan N: Processing and activation of latent heparanase occurs
in lysosomes. J Cell Sci. 117:2249–2258. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Levy-Adam F, Abboud-Jarrous G, Guerrini M,
Beccati D, Vlodavsky I and Ilan N: Identification and
characterization of heparin/heparan sulfate binding domains of the
endoglycosidase heparanase. J Biol Chem. 280:20457–20466. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yuan L, Hu J, Luo Y, Liu Q, Li T, Parish
CR, Freeman C, Zhu X, Ma W, Hu X, et al: Upregulation of heparanase
in high-glucose-treated endothelial cells promotes endothelial cell
migration and proliferation and correlates with Akt and
extracellular-signal-regulated kinase phosphorylation. Mol Vis.
18:1684–1695. 2012.PubMed/NCBI
|
|
27
|
Riaz A, Ilan N, Vlodavsky I, Li JP and
Johansson S: Characterization of heparanase-induced
phosphatidylinositol 3-kinase-AKT activation and its integrin
dependence. J Biol Chem. 288:12366–12375. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sotnikov I, Hershkoviz R, Grabovsky V,
Ilan N, Cahalon L, Vlodavsky I, Alon R and Lider O: Enzymatically
quiescent heparanase augments T cell interactions with VCAM-1 and
extracellular matrix components under versatile dynamic contexts. J
Immunol. 172:5185–5193. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Goldshmidt O, Zcharia E, Cohen M, Aingorn
H, Cohen I, Nadav L, Katz BZ, Geiger B and Vlodavsky I: Heparanase
mediates cell adhesion independent of its enzymatic activity. FASEB
J. 17:1015–1025. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nadir Y and Brenner B: Heparanase-A Link
between Coagulation, Angiogenesis, and Cancer. Rambam Maimonides
Med J. 3:e00022012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Irby RB and Yeatman TJ: Role of Src
expression and activation in human cancer. Oncogene. 19:5636–5642.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mittelstadt PR, Salvador JM, Fornace AJ Jr
and Ashwell JD: Activating p38 MAPK: New tricks for an old kinase.
Cell Cycle. 4:1189–1192. 2005. View Article : Google Scholar : PubMed/NCBI
|
